Table 1. Basic characteristics of study cohort.
| Parameter | All patients n=179 | First quartile n=43 | Second quartile n=46 | Third quartile n=45 | Fourth quartile n=45 |
|---|---|---|---|---|---|
| Age (years), median (range) | 53 (18–77) | 45 (18–65) | 51.5 (25–69) | 57 (19–76) | 60 (22–77) |
| Male gender, n (%) | 98 (55) | 19 (44.2) | 22 (47.8) | 30 (66.7) | 27 (60.0) |
| Category of disease, n (%) | |||||
| Primary AML | 119 (66.5) | 33 (76.7) | 35 (76.1) | 21 (46.7) | 30 (66.7) |
| Secondary AML | 60 (33.5) | 10 (23.3) | 11 (23.9) | 24 (53.3) | 15 (33.3) |
| Disease riska, n (%) | |||||
| Favorable | 27 (15.1) | 6 (14.0) | 9 (19.6) | 5 (11.1) | 7 (15.6) |
| Intermediate | 108 (60.3) | 30 (70.0) | 26 (56.5) | 30 (66.7) | 22 (48.9) |
| Adverse | 41 (22.9) | 7 (16.3) | 10 (21.7) | 10 (22.2) | 14 (31.1) |
| Missing | 3 (1.7) | 0 (0) | 1 (2.2) | 0 (0) | 2 (4.4) |
| TRM score, median (range) | 4.67 (0.15–77.50) | 1.46 (0.15–2.28) | 3.18 (2.31–4.54) | 6.13 (4.67–10.25) | 23.36 (10.81–77.50) |
| Performance status, n (%) | |||||
| 0–1 | 132 (73.7) | 42 (97.7) | 46 (100) | 37 (82.2) | 7 (15.6) |
| 2 | 15 (8.4) | 0 (0) | 0 (0) | 6 (13.3) | 9 (0.2) |
| 3 | 18 (10.1) | 1 (2.3) | 0 (0) | 1 (2.2) | 16 (35.6) |
| 4 | 14 (7.8) | 0 (0) | 0 (0) | 1 (2.2) | 13 (28.9) |
| Total WBC ( × 103/μl) | 13.1 (0.1–372.0) | 16.1 (0.7–76.0) | 5.4 (0.5–92.2) | 3.2 (0.2–131.4) | 31.9 (0.1–372.0) |
| % Peripheral blood blasts | 25.9 (0–96.0) | 49.0 (0–92.0) | 15.1 (0–94.0) | 15.8 (0–96.0) | 42.0 (0–93.0) |
| Platelets ( × 103/μl) | 50 (5–547) | 106 (17–547) | 48.5 (12–215) | 46 (5–138) | 40 (8–93) |
| Creatinine (mg/dl) | 0.9 (0.42–4.26) | 0.8 (0.5–1.5) | 0.83 (0.6–1.6) | 0.9 (0.42–2.90) | 1.2 (0.5–4.26) |
| Albumin (g/dL) | 3.2 (1.4–4.6) | 3.5 (2.2–4.5) | 3.5 (1.9–4.6) | 3.1 (2.1–4.1) | 2.7 (1.4–4.1) |
Abbreviations: AML, acute myeloid leukemia; TRM, treatment-related mortality.
Treatment regimens included 7+3 (N=150), 7+3+gemtuzumab ozogamicin (N=14), 7+3+cladribine (N=2), 7+3+sorafenib (N=3), 7+3+demethylating agent (N=3), 7+3+high-dose pravastatin (N=2) and 7+3+all-trans retinoic acid (N=5).
a
Risk based on modified Medical Research Council (MRC) criteria.